Literature DB >> 29264687

[Antibodies as treatment option in older adults].

M Gosch1, S Wicklein2.   

Abstract

Monoclonal antibodies are already used for many different clinical indications. Besides oncology and rheumatology, denosumab is the only antibody that is currently prescribed in older adults with osteoporosis; however, apart from osteoporosis there might be more possible indications for the use of antibodies in chronic diseases and geriatric syndromes. Particularly, with respect to sarcopenia the transition to "doping for older adults" seems to be fluent. The present review provides an overview on the newest developments and prospective options.

Entities:  

Keywords:  Cardiovascular diseases; Dementia; Infection; Osteoporosis; Sarcopenia

Mesh：

Substances：

Year:  2017        PMID： 29264687     DOI： 10.1007/s00391-017-1352-x

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN： 0948-6704            Impact factor:   1.281


  28 in total

Review 1.  Myostatin and sarcopenia: opportunities and challenges - a mini-review.

Authors:  Thomas A White; Nathan K LeBrasseur
Journal:  Gerontology       Date:  2014-01-17       Impact factor: 5.140

2.  Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.

Authors:  Clemens Becker; Stephen R Lord; Stephanie A Studenski; Stuart J Warden; Roger A Fielding; Christopher P Recknor; Marc C Hochberg; Serge L Ferrari; Hubert Blain; Ellen F Binder; Yves Rolland; Serge Poiraudeau; Charles T Benson; Stephen L Myers; Leijun Hu; Qasim I Ahmad; Kelli R Pacuch; Elisa V Gomez; Olivier Benichou
Journal:  Lancet Diabetes Endocrinol       Date:  2015-10-27       Impact factor: 32.069

3.  A Phase 2 Randomized Study Investigating the Efficacy and Safety of Myostatin Antibody LY2495655 versus Placebo in Patients Undergoing Elective Total Hip Arthroplasty.

Authors:  L Woodhouse; R Gandhi; S J Warden; S Poiraudeau; S L Myers; C T Benson; L Hu; Q I Ahmad; P Linnemeier; E V Gomez; O Benichou
Journal:  J Frailty Aging       Date:  2016

4.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

Authors:  Felicia Cosman; Daria B Crittenden; Jonathan D Adachi; Neil Binkley; Edward Czerwinski; Serge Ferrari; Lorenz C Hofbauer; Edith Lau; E Michael Lewiecki; Akimitsu Miyauchi; Cristiano A F Zerbini; Cassandra E Milmont; Li Chen; Judy Maddox; Paul D Meisner; Cesar Libanati; Andreas Grauer
Journal:  N Engl J Med       Date:  2016-09-18       Impact factor: 91.245

5.  Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice.

Authors:  João-Paulo G Camporez; Max C Petersen; Abulizi Abudukadier; Gabriela V Moreira; Michael J Jurczak; Glenn Friedman; Christopher M Haqq; Kitt Falk Petersen; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

6.  10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

Authors:  Henry G Bone; Rachel B Wagman; Maria L Brandi; Jacques P Brown; Roland Chapurlat; Steven R Cummings; Edward Czerwiński; Astrid Fahrleitner-Pammer; David L Kendler; Kurt Lippuner; Jean-Yves Reginster; Christian Roux; Jorge Malouf; Michelle N Bradley; Nadia S Daizadeh; Andrea Wang; Paula Dakin; Nicola Pannacciulli; David W Dempster; Socrates Papapoulos
Journal:  Lancet Diabetes Endocrinol       Date:  2017-05-22       Impact factor: 32.069

7.  Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Authors:  Paul M Ridker; James Revkin; Pierre Amarenco; Robert Brunell; Madelyn Curto; Fernando Civeira; Marcus Flather; Robert J Glynn; Jean Gregoire; J Wouter Jukema; Yuri Karpov; John J P Kastelein; Wolfgang Koenig; Alberto Lorenzatti; Pravin Manga; Urszula Masiukiewicz; Michael Miller; Arend Mosterd; Jan Murin; Jose C Nicolau; Steven Nissen; Piotr Ponikowski; Raul D Santos; Pamela F Schwartz; Handrean Soran; Harvey White; R Scott Wright; Michal Vrablik; Carla Yunis; Charles L Shear; Jean-Claude Tardif
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

8.  Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.

Authors:  Silvano Adami; Cesar Libanati; Steven Boonen; Steven R Cummings; Pei-Ran Ho; Andrea Wang; Ethel Siris; Joseph Lane; Jonathan D Adachi; Mohit Bhandari; Luiz de Gregorio; Nigel Gilchrist; George Lyritis; Gerd Möller; Santiago Palacios; Karel Pavelka; Resch Heinrich; Christian Roux; Daniel Uebelhart
Journal:  J Bone Joint Surg Am       Date:  2012-12-05       Impact factor: 5.284

9.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

Authors:  Kenneth G Saag; Jeffrey Petersen; Maria Luisa Brandi; Andrew C Karaplis; Mattias Lorentzon; Thierry Thomas; Judy Maddox; Michelle Fan; Paul D Meisner; Andreas Grauer
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

10.  Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis.

Authors:  Kenneth E S Poole; Graham M Treece; Andrew H Gee; Jacques P Brown; Michael R McClung; Andrea Wang; Cesar Libanati
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.